These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 1938564)
1. 5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Baranowska-Kortylewicz J; Makrigiorgos GM; Van den Abbeele AD; Berman RM; Adelstein SJ; Kassis AI Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1541-51. PubMed ID: 1938564 [TBL] [Abstract][Full Text] [Related]
2. Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. Kassis AI; Tumeh SS; Wen PY; Baranowska-Kortylewicz J; Van den Abbeele AD; Zimmerman RE; Carvalho PA; Garada BM; DeSisto WC; Bailey NO; Castronovo FP; Mariani G; Black PM; Adelstein SJ J Nucl Med; 1996 Apr; 37(4 Suppl):19S-22S. PubMed ID: 8676198 [TBL] [Abstract][Full Text] [Related]
8. Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Kassis AI; Adelstein SJ; Mariani G Q J Nucl Med; 1996 Sep; 40(3):301-19. PubMed ID: 8961807 [TBL] [Abstract][Full Text] [Related]
9. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. Van den Abbeele AD; Tutrone RF; Berman RM; Baranowska-Kortylewicz J; Barclay PD; Richie JP; Adelstein SJ; Kassis AI J Nucl Med; 1996 Feb; 37(2):315-20. PubMed ID: 8667069 [TBL] [Abstract][Full Text] [Related]
10. Intrathecal 5-[125I]iodo-2'-deoxyuridine in a rat model of leptomeningeal metastases. Sahu SK; Wen PY; Foulon CF; Nagel JS; Black PM; Adelstein SJ; Kassis AI J Nucl Med; 1997 Mar; 38(3):386-90. PubMed ID: 9074525 [TBL] [Abstract][Full Text] [Related]
11. Bullatacin--in vivo and in vitro experience in an ovarian cancer model. Holschneider CH; Johnson MT; Knox RM; Rezai A; Ryan WJ; Montz FJ Cancer Chemother Pharmacol; 1994; 34(2):166-70. PubMed ID: 8194168 [TBL] [Abstract][Full Text] [Related]
12. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. Macapinlac HA; Kemeny N; Daghighian F; Finn R; Zhang J; Humm J; Squire O; Larson SM J Nucl Med; 1996 Apr; 37(4 Suppl):25S-29S. PubMed ID: 8676200 [TBL] [Abstract][Full Text] [Related]
13. Radiotoxicity of 5-[123I]iodo-2'-deoxyuridine in V79 cells: a comparison with 5-[125I]iodo-2'-deoxyuridine. Makrigiorgos GM; Kassis AI; Baranowska-Kortylewicz J; McElvany KD; Welch MJ; Sastry KS; Adelstein SJ Radiat Res; 1989 Jun; 118(3):532-44. PubMed ID: 2727274 [TBL] [Abstract][Full Text] [Related]
14. Tumor uptake and mitotic activity pattern of 5-[125I]iodo-2'- deoxyuridine after intravesical infusion in patients with bladder cancer. Mariani G; Collecchi P; Baldassarri S; Di Luca L; Buralli S; Fontanini G; Baranowska-Kortylewicz J; Adelstein SJ; Kassis AI J Nucl Med; 1996 Apr; 37(4 Suppl):16S-19S. PubMed ID: 8676197 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic application of iodine-125 labeled iododeoxyuridine in an early ascites tumour model. Bloomer WD; Adelstein SJ Curr Top Radiat Res Q; 1978 Jan; 12(1-4):513-25. PubMed ID: 639561 [TBL] [Abstract][Full Text] [Related]
16. The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy. Schaffland AO; Delaloye AB; Kosinski M; Dupertuis YM; Buchegger F Nucl Med Commun; 2004 May; 25(5):461-8. PubMed ID: 15100504 [TBL] [Abstract][Full Text] [Related]
17. Targeting tumors with iodine-123 labeled deoxyuridine: distribution and DNA binding. Thakur ML; Li J; Kim SM; Zhang JJ; Andrews D Cancer Detect Prev; 1999; 23(1):72-7. PubMed ID: 9892993 [TBL] [Abstract][Full Text] [Related]
18. In vivo therapy of neoplastic meningitis with methotrexate and 5. Kassis AI; Dahman BA; Adelstein SJ Acta Oncol; 2000; 39(6):731-7. PubMed ID: 11130012 [TBL] [Abstract][Full Text] [Related]